Daratumumab-pomalidomide-dexamethasone for first-relapse myeloma
Part of Blood & lymphatic, Cancer, Heart & circulation, Immune system & allergy clinical trials.
This trial tests a combination of three drugs (daratumumab, pomalidomide, and dexamethasone) for people whose multiple myeloma has returned for the first time after initial treatment with RVD. The goal is to see if this new combination can control the cancer.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 or older.
- You have multiple myeloma that has come back for the first time after initial treatment.
- Your first treatment included a proteasome inhibitor (like bortezomib) and an immunomodulator (like lenalidomide) – often called RVD.
- Your cancer responded (at least partially) to that first treatment.
- You have not been treated with daratumumab or pomalidomide before.
- You do not have inactive or smoldering myeloma, or other active cancers (with some exceptions).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new medicine (GR1803) against a standard combination treatment for people whose multiple myeloma has come back or stopped responding to prior therapies. It aims to see if the new drug works better.
This trial tests a combination of two drugs, daratumumab and lenalidomide, for patients with multiple myeloma that has not responded to previous treatments. It aims to see if this regimen can help when other therapies have stopped working.
This trial tests a new combination of four drugs for people with high-risk multiple myeloma that has come back or did not respond to initial treatment. The goal is to see if this combination is safe and effective.
This trial tests a new combination of drugs for people with multiple myeloma whose cancer did not respond to or returned after one prior treatment with lenalidomide. The goal is to see if this combination is safe and effective.
This study tests an investigational drug for people with multiple myeloma, a type of blood cancer. It aims to see how safe and effective the treatment is for patients who are newly diagnosed or have relapsed after prior therapy.
This trial tests a combination of four drugs (daratumumab, bortezomib, lenalidomide, and dexamethasone) for people newly diagnosed with a high-risk form of multiple myeloma called double-hit myeloma. It aims to see if this drug combo can improve outcomes for those with two or more high-risk genetic changes.
Hear when a new Multiple myeloma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.